Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers
Authors
Keywords
-
Journal
MOLECULAR BIOLOGY REPORTS
Volume 49, Issue 1, Pages 717-733
Publisher
Springer Science and Business Media LLC
Online
2021-11-05
DOI
10.1007/s11033-021-06863-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
- (2021) Anna Ianza et al. Frontiers in Cell and Developmental Biology
- STAT3 pathway as a molecular target for resveratrol in breast cancer treatment
- (2021) Zeynab Kohandel et al. Cancer Cell International
- Invasion and Metastasis as a Central Hallmark of Breast Cancer
- (2021) Trishna Saha et al. Journal of Clinical Medicine
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
- (2020) F. Mosele et al. ANNALS OF ONCOLOGY
- G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
- (2020) Kaitlyn J. Andreano et al. BREAST CANCER RESEARCH AND TREATMENT
- RNA sequencing reveals an additional Crz1-binding motif in promoters of its target genes in the human fungal pathogen Candida albicans
- (2020) Huihui Xu et al. Cell Communication and Signaling
- Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial
- (2020) Amelia McCartney et al. CLINICAL CANCER RESEARCH
- ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis
- (2020) Changliang Chen et al. ONCOGENE
- Nausea and Vomiting: a Palliative Care Imperative
- (2020) Rita J. Wickham Current Oncology Reports
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling
- (2020) Deepak Parashar et al. CANCER RESEARCH
- Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
- (2019) Elaine Reguera-Nuñez et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Exploring Biomarkers of Phosphoinositide 3‐Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer
- (2019) Virginia G. Kaklamani et al. ONCOLOGIST
- Rhabdomyosarcoma
- (2019) Stephen X. Skapek et al. Nature Reviews Disease Primers
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
- (2019) Muriel Laine et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic characterization of metastatic breast cancers
- (2019) François Bertucci et al. NATURE
- Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
- (2019) Aradhana Rani et al. Frontiers in Endocrinology
- PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy
- (2019) William Jacot et al. BREAST CANCER RESEARCH AND TREATMENT
- Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer
- (2019) Xiaofen Zhang et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
- (2019) Claudio Vernieri et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
- (2019) Amelia McCartney et al. EUROPEAN JOURNAL OF CANCER
- Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
- (2019) Amelia McCartney et al. Frontiers in Oncology
- Practical treatment strategies and future directions after progression on CDK4/6 inhibition and endocrine therapy in advanced HR+/HER2- breast cancer
- (2019) Sarah Sammons et al. Clinical Breast Cancer
- Pathways to Endocrine Therapy Resistance in Breast Cancer
- (2019) Md. Moquitul Haque et al. Frontiers in Endocrinology
- Overview of the relevance of PI3K pathway in HR-positive breast cancer
- (2019) N Vasan et al. ANNALS OF ONCOLOGY
- Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
- (2019) M Brandão et al. ANNALS OF ONCOLOGY
- Efficacy of PI3K inhibitors in advanced breast cancer
- (2019) B Verret et al. ANNALS OF ONCOLOGY
- Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance
- (2019) Alex Pearson et al. CLINICAL CANCER RESEARCH
- The potential of ctDNA analysis in breast cancer
- (2019) Eleni Tzanikou et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
- (2019) Carlotta Costa et al. Cancer Discovery
- The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
- (2019) Irene De Santo et al. Cancers
- Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
- (2019) Margaret von Mehren et al. CLINICAL CANCER RESEARCH
- miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer
- (2019) Deepak Parashar et al. Cell Reports
- JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance
- (2018) Tianyi Wang et al. Cell Metabolism
- PI3K inhibition to overcome endocrine resistance in breast cancer
- (2018) Niamh M Keegan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)
- (2018) Pedro Barata et al. INVESTIGATIONAL NEW DRUGS
- Estrogen Receptor‐Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
- (2018) Adam M. Brufsky et al. ONCOLOGIST
- CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
- (2018) Filipa Lynce et al. PHARMACOLOGY & THERAPEUTICS
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
- (2018) Ben O’Leary et al. Nature Communications
- Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
- (2018) Martina Bonechi et al. Oncotarget
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
- (2018) Neil Portman et al. ENDOCRINE-RELATED CANCER
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
- (2018) Kai Zhang et al. Cancer Management and Research
- The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy
- (2018) Marco Fiorillo et al. Aging-US
- Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
- (2018) E S Sokol et al. ANNALS OF ONCOLOGY
- Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
- (2018) Małgorzata Szostakowska et al. BREAST CANCER RESEARCH AND TREATMENT
- Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
- (2018) Dinja T. Kruger et al. BRITISH JOURNAL OF CANCER
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case
- (2017) Valentina Appierto et al. SEMINARS IN CANCER BIOLOGY
- Prognostic and predictive biomarkers in breast cancer: Past, present and future
- (2017) Andrea Nicolini et al. SEMINARS IN CANCER BIOLOGY
- Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?
- (2017) Florian Reinhardt et al. TUMOR BIOLOGY
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
- (2017) Takashi Takeshita et al. Oncotarget
- IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules
- (2017) Nikolaos A. Afratis et al. Scientific Reports
- Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
- (2017) Tomás Reinert et al. Therapeutic Advances in Medical Oncology
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
- (2016) Jennifer L. Hsu et al. CANCER AND METASTASIS REVIEWS
- New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies
- (2016) Rachel C. Jankowitz et al. CLINICAL CANCER RESEARCH
- Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
- (2016) Fabrice André et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Proteogenomics connects somatic mutations to signalling in breast cancer
- (2016) Philipp Mertins et al. NATURE
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Targeting the RB-E2F pathway in breast cancer
- (2016) J Johnson et al. ONCOGENE
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
- (2016) Florian Clatot et al. Oncotarget
- Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
- (2016) Rekha Gyanchandani et al. Oncotarget
- Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
- (2016) Debora de Melo Gagliato et al. Oncotarget
- Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer
- (2016) Pradeep Chaluvally-Raghavan et al. Cell Reports
- Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
- (2016) Sean W Fanning et al. eLife
- Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
- (2015) Amir Sonnenblick et al. BMC Medicine
- A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
- (2015) Otília Menyhart et al. CURRENT CANCER DRUG TARGETS
- Increased Expression of Forkhead Box M1 Is Associated with Aggressive Phenotype and Poor Prognosis in Estrogen Receptor-Positive Breast Cancer
- (2015) Hyein Ahn et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells
- (2015) Panagiotis Bouris et al. MATRIX BIOLOGY
- Endocrine resistance in breast cancer – An overview and update
- (2015) Robert Clarke et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Genomic tumor evolution of breast cancer
- (2015) Fumiaki Sato et al. Breast Cancer
- Optimal management of hormone receptor positive metastatic breast cancer in 2016
- (2015) Tomas Reinert et al. Therapeutic Advances in Medical Oncology
- Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression
- (2015) Guangchao Li et al. Oncotarget
- Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer
- (2014) L. M. Arthur et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
- (2014) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: Focus on the role and impact of proteoglycans
- (2013) Spyros S. Skandalis et al. MATRIX BIOLOGY
- Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells
- (2013) Deborah A Sanders et al. GENOME BIOLOGY
- The current state of breast cancer classification
- (2012) G. Viale ANNALS OF ONCOLOGY
- Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
- (2012) Albert C. Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers
- (2012) Rita Nahta et al. BREAST CANCER RESEARCH AND TREATMENT
- Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer
- (2012) Nathan R West et al. ENDOCRINE-RELATED CANCER
- Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
- (2011) A Bergamaschi et al. ONCOGENE
- FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance
- (2010) J Millour et al. ONCOGENE
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started